Key Highlights

Reinforce your 7 + 3 AML treatment with NICE and SMC approved MYLOTARG™ dosing3,4

Compared with intensive chemotherapy alone, fractionated dosing of MYLOTARG™ plus intensive chemotherapy in de novo AML offers:

 

With MYLOTARG™, reinforce AML therapy by prolonging remission in more
patients than with intensive chemotherapy alone*1,2

*MYLOTARG™ is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated, de novo, CD33‑positive AML, except acute promyelocytic leukaemia. 
AML, acute myeloid leukaemia; EFS, event-free survival; RFS, relapse-free survival; NICE, National institute for Heath and Care Excellence; SMC, Scottish Medicines Consortium

References

  1. MYLOTARG™ Summary of Marketing Product Characteristics.
  2. Lambert J, et al. Haematologica 2019;104:113–119.
  3. National Institute for Health and Care Excellence. Technolgy appraisal guidance (TA545): Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (Published 14 November 2018). Available at: https://www.nice.org.uk/guidance/ta545/chapter/1-Recommendations [accessed December 2019].
  4. Scottish Medicines Consortium. Gemtuzumab ozogamicin (MYLOTARG): SMC2089 (Published: 08 October 2018). Available at: https://www.scottishmedicines.org.uk/medicines-advice/gemtuzumab-ozogami... [accessed December 2019]

PP-MYL-GBR-0091. December 2019

Prescribing information

MYLOTARG™ (gemtuzumab ozogamicin) 5 mg powder for concentrate for solution for infusion
Legal category: Prescription only medicine.  Cost: £6,300 per vial.

Click here to access the MYLOTARG Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.

 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Cytarabine 20 mg/mL and 100 mg/mL solution for infusion or injection

Legal category: Prescription only medicine. Basic NHS price: Cytarabine 100 mg/mL, supplied as single vials containing 100 mg/mL cytarabine in 10 mL (1 g), £39.00 or 20 mL (2 g), £77.50. Cytarabine 20 mg/mL supplied as vials containing 20 mg/mL cytarabine in 5 mL (100 mg) in packs of 5, £20.48 or 25 mL (500 mg) as single vials, £19.50. 
Click to access the cytarabine
20 mg/mL and 100 mg/mL Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.